Nuvalent Completes Registered Follow-On Offering Raising Approximately $543.4 Million

"Simpson Thacher represented the underwriters led by J.P. Morgan, Jefferies, TD Cowen and Cantor in Nuvalent's registered follow-on offering of 5,693,070 Class A shares, which raised approximately $543.4 million in aggregate gross proceeds for Nuvalent and the selling stockholders."

Simpson Thacher represented the underwriters, led by J.P. Morgan, Jefferies, TD Cowen and Cantor, in connection with Nuvalent, Inc.'s registered follow-on offering. The offering consisted of 5,693,070 shares of Class A common stock sold by Nuvalent, Inc. and certain selling stockholders and raised approximately $543.4 million in aggregate gross proceeds for Nuvalent and the selling stockholders. Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Simpson Thacher represented the underwriters, led by J.P. Morgan, Jefferies, TD Cowen and Cantor, with a team composed by: John O’Connell, Evan Zuckerman, Julie De Keukeleire and Anthony Kuan (Capital Markets); Vanessa Burrows, Alison Peters and Jacob Madden (Healthcare); Paige Brinton (IP); Drew Purcell and Michael Mann (Tax); Pasco Struhs (ECEB); and Andrew Pagliughi (FINRA and Blue Sky).

Nuvalent Completes Registered Follow-On Offering Raising Approximately $543.4 Million

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads